Skip to main content

Advertisement

Table 1 Study characteristics

From: Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis

Author Year Group N Age M/F Disease LVEF (%) Dose Route Follow-up Imaging
Bartolucci 2015 BMNC 12 58 ± 14 9/3 DCM ≤ 40 8.19 × 106 IC ECHO
Control 11 57 ± 11 8/3
Bartolucci 2017 BMSC 15 57.33 ± 10.05 12/3 DCM ≤ 40 1 × 106 IV 12 months ECHO
Control 15 57.2 ± 11.64 14/1
Chang 2010 BMNC 12 38.6 ± 9.8 16/8 DCM 2 × 108 IM 6 months ECHO
Control 12
Chen 2006 BMSC 22 59.3 ± 6.8 19/3 IDCM < 40 5 × 106 IC 12 months SPECT
Control 62 57.8 ± 7.2 21/2
Chen 2008 BMNC 71 53 ± 15 44/17 DCM < 45 IC 24 months ECG
Control 187 54 ± 13 136/51
Hamshere 2015 BMNC 15 57.67 ± 12.32 10/5 DCM < 40 2.16 × 108 IC 12 months CMR
Control 14 54.87 ± 10.86 9/6
Heldman 2014 BMNC 19 57.1 ± 10.6 18/1 IDCM < 50 IM 12 months CMR
Control 10 61.3 ± 9.0 10/0
Henry 2014 Ixmyelocel-T 39 64.7 ± 9 21/0 IDCM < 30 2.95 × 108 IM 12 months ECG/SPECT
Control 20 63.2 ± 12 9/0
Martino 2015 BMNC 82 49.6 ± 11.1 53/25 NIDCM < 35 2.36 × 108 IC 12 months ECHO
Control 78 51 ± 1.11 60/22
Nesteruk 2017 BMNC 114 66.7 ± 8.3 105/9 IDCM < 45 3.9 × 106 IM 4–14 years ECHO
Control 36 68.6 ± 5.78 22/4
Patel 2016 Ixmyelocel-T 59 65.3 ± 8.49 55/3 IDCM < 35 IM 12 months ECHO
Control 55 64.7 ± 9.94 45/6
Perin 2004 BMNC 11 56.5 ± 7.8 9/2 DCM < 40 IM 12 months SPECT
Control 9 58.9 ± 7.6 8/1
Sant’Anna 2014 BMNC 15 48.3 ± 8.71 13/7 NIDCM < 35 1.06 × 108 IM 12 months ECHO/CMR
Control 9 51.6 ± 7.79 5/4
Seth 2010 BMNC 41 45 ± 15 33/8 DCM < 40 1.68 × 108 IC 36 months ECHO
Control 40 49 ± 9 35/4
Song 2008 BMSC 27    DCM < 50 2 × 106 IM 6 months Ultrasound
Control 25   
Vrtovec 2011 BMSC 28 52 ± 8 26/2 DCM < 30 1.13 × 108 IC 12 months ECHO
Control 28 54 ± 7 23/4
Vrtovec 2013 BMSC 55 53 ± 8 45/10 DCM < 30 IC 60 months ECHO
Control 55 55 ± 7 44/11
Wang 2006 BMSC 12 54 ± 11.1 9/3 DCM < 45 5.86 × 105 IC 12 months ECHO
Control 12 58.4 ± 11 8/4
Xiao 2017 BMNC 16 49.5 ± 11.6 9/7 DCM < 40 5.1 × 108 IC 3 months SPECT
BMSC 17 51.6 ± 12.2 12/5
Control 20 54.4 ± 11.6 14/6
Yan 2012 BMSC 18 58 ± 9.9 12/6 DCM < 40 1 × 108 IC 12 months SPECT/ECHO
Control 20 58.2 ± 9.8 14/6
  1. M/F male/female, LVEF left ventricular ejection fraction, IC intracoronary, IM intramyocardial, IV intravenous, QS quality assessment, BMNC bone marrow mononuclear cells, BMSC bone mesenchymal stem cells, DCM dilated cardiomyopathy, IDCM ischemic dilated cardiomyopathy, NIDCM non-ischemia dilated cardiomyopathy, ICM ischemic cardiomyopathy, CCC Chagas cardiomyopathy, CMR cardiovascular magnetic resonance imaging, ECHO echocardiography, ECG electrocardiogram, SPECT single-photon emission-computed tomography